The complex role of SIRT6 in carcinogenesis

Carcinogenesis

Volumn 37, Issue 2, 2015, Pages 108-118

  Lerrer, Batia ^a   Gertler, Asaf A ^a   Cohen, Haim Y ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FAT; GLUCOSE; LIPID; SIRTUIN 6; SIRT6 PROTEIN, HUMAN; SIRTUIN;

APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; DNA REPAIR; GENOMIC INSTABILITY; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLYCOLYSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; LIFESPAN; LIPID METABOLISM; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; ANIMAL; LONGEVITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; HOMEOSTASIS; HUMANS; LONGEVITY; NEOPLASMS; SIRTUINS;

EID: 84962026722     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv167     Document Type: Review

References (118)

1. Gertler, A.A. et al. (2013) SIRT6, a protein with many faces. Biogerontology, 14, 629-639.
2. Landry, J. et al. (2000) The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. USA, 97, 5807-5811.
3. Kaeberlein, M. et al. (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev., 13, 2570-2580.
4. Imai, S. et al. (2000) Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 403, 795-800.
5. Houtkooper, R.H. et al. (2012) Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol., 13, 225-238.
6. Michishita, E. et al. (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell, 16, 4623-4635.
7. Naiman, S. et al. (2012) The contentious history of sirtuin debates. Rambam Maimonides Med. J., 3, e0022.
8. Rajendran, R. et al. (2011) Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J. Biomed. Biotechnol., 2011, 368276.
9. Haigis, M.C. et al. (2010) Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol., 5, 253-295.
10. Jiang, H. et al. (2013) SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine. Nature, 496, 110-113.
11. Pan, P.W. et al. (2011) Structure and biochemical functions of SIRT6. J. Biol. Chem., 286, 14575-14587.
12. Mostoslavsky, R. et al. (2006) Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell, 124, 315-329.
13. Kanfi, Y. et al. (2012) The sirtuin SIRT6 regulates lifespan in male mice. Nature, 483, 218-221.
14. van Heemst, D. (2010) Insulin, IGF-1 and longevity. Aging Dis., 1, 147-157.
15. Kanfi, Y. et al. (2010) SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell, 9, 162-173.
16. Boutant, M. et al. (2014) SIRT1 metabolic actions: Integrating recent advances from mouse models. Mol. Metab., 3, 5-18.
17. Kanfi, Y. et al. (2008) Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett., 582, 543-548.
18. Kanfi, Y. et al. (2008) Regulation of SIRT1 protein levels by nutrient availability. FEBS Lett., 582, 2417-2423.
19. Cheng, H.L. et al. (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA, 100, 10794-10799.
20. Etchegaray, J.P. et al. (2013) The histone deacetylase SIRT6: at the crossroads between epigenetics, metabolism and disease. Curr. Top. Med. Chem., 13, 2991-3000.
21. Kim, H.S. et al. (2010) Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab., 12, 224-236.
22. McDonnell, E. et al. (2015) SIRT3 regulates progression and development of diseases of aging. Trends Endocrinol. Metab., 26, 486-492.
23. Hirschey, M.D. et al. (2011) SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell, 44, 177-190.
24. Kim, H.S. et al. (2010) SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell, 17, 41-52.
25. Finley, L.W. et al. (2011) SIRT3 opposes reprogramming of cancer cell metabolism through HIF1a destabilization. Cancer Cell, 19, 416-428.
26. Michishita, E. et al. (2008) SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature, 452, 492-496.
27. Michishita, E. et al. (2009) Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. Cell Cycle, 8, 2664-2666.
28. Yang, B. et al. (2009) The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability. Cell Cycle, 8, 2662-2663.
29. Görisch, S.M. et al. (2005) Histone acetylation increases chromatin accessibility. J. Cell Sci., 118(Pt 24), 5825-5834.
30. Gil, R. et al. (2013) SIRT6 exhibits nucleosome-dependent deacetylase activity. Nucleic Acids Res., 41, 8537-8545.
31. Kaidi, A. et al. (2010) Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science, 329, 1348-1353.
32. Dominy, J.E. Jr et al. (2012) The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol. Cell, 48, 900-913.
33. Zhong, L. et al. (2010) The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell, 140, 280-293.
34. Seagroves, T.N. et al. (2001) Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol., 21, 3436-3444.
35. Vander Heiden, M.G. et al. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-1033.
36. Sebastián, C. et al. (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell, 151, 1185-1199.
37. Lerrer, B. et al. (2013) The guardian: metabolic and tumour-suppressive effects of SIRT6. EMBO J., 32, 7-8.
38. van Riggelen, J. et al. (2010) MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer, 10, 301-309.
39. Choe, M. et al. (2015) The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. J. Cell. Biochem., 116, 2210-2226.
40. Wu, M. et al. (2014) Expression and function of SIRT6 in muscle invasive urothelial carcinoma of the bladder. Int. J. Clin. Exp. Pathol., 7, 6504-6513.
41. Wu, M. et al. (2015) E2F1 enhances glycolysis through suppressing Sirt6 transcription in cancer cells. Oncotarget, 6, 11252-11263.
42. Zhang, P. et al. (2014) Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc. Natl. Acad. Sci. USA, 111, 10684-10689.
43. Wolin, K.Y. et al. (2010) Obesity and cancer. Oncologist, 15, 556-565.
44. Polednak, A.P. (2008) Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect. Prev., 32, 190-199.
45. Elhanati, S. et al. (2013) Multiple regulatory layers of SREBP1/2 by SIRT6. Cell Rep., 4, 905-912.
46. Horton, J.D. (2002) Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans., 30(Pt 6), 1091-1095.
47. Horton, J.D. et al. (1999) Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol., 10, 143-150.
48. Fajas, L. et al. (1999) Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol. Cell. Biol., 19, 5495-5503.
49. Le Lay, S. et al. (2002) Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target. J. Biol. Chem., 277, 35625-35634.
50. Ray, A. et al. (1995) Concerted participation of NF-kappa B and C/EBP heteromer in lipopolysaccharide induction of serum amyloid A gene expression in liver. J. Biol. Chem., 270, 7365-7374.
51. Yang, S.J. et al. (2011) Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One, 6, e17057.
52. Sounni, N.E. et al. (2014) Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab., 20, 280-294.
53. Lombard, D.B. et al. (2005) DNA repair, genome stability, and aging. Cell, 120, 497-512.
54. Bassing, C.H. et al. (2004) The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst)., 3, 781-796.
55. Lombard, D.B. (2009) Sirtuins at the breaking point: SIRT6 in DNA repair. Aging, 1, 12-16.
56. McCord, R.A. et al. (2009) SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging, 1, 109-121.
57. Mao, Z. et al. (2011) SIRT6 promotes DNA repair under stress by activating PARP1. Science, 332, 1443-1446.
58. Toiber, D. et al. (2013) SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling. Mol. Cell, 51, 454-468.
59. Van Meter, M. et al. (2011) SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle, 10, 3153-3158.
60. Van Meter, M. et al. (2014) SIRT6 represses LINE1 retrotransposons by ribosylating KAP1 but this repression fails with stress and age. Nat. Commun., 5, 5011.
61. Liu, T. et al. (2004) Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene, 23, 39-48.
62. O'Connor, D.S. et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA, 97, 13103-13107.
63. Shin, S. et al. (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry, 40, 1117-1123.
64. Banks, D.P. et al. (2000) Survivin does not inhibit caspase-3 activity. Blood, 96, 4002-4003.
65. Mesri, M. et al. (2001) Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest., 108, 981-990.
66. Adida, C. et al. (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am. J. Pathol., 152, 43-49.
67. Ambrosini, G. et al. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3, 917-921.
68. Tamm, I. et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res., 58, 5315-5320.
69. Altieri, D.C. et al. (1999) Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest., 79, 1327-1333.
70. Fukuda, T. et al. (2015) Putative tumor suppression function of SIRT6 in endometrial cancer. FEBS Lett., 589, 2274-2281.
71. Min, L. et al. (2012) Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol., 14, 1203-1211.
72. Zhang, J. et al. (2015) The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression. Eur. Rev. Med. Pharmacol. Sci., 19, 818-824.
73. Jung, S.G. et al. (2010) Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci., 101, 1977-1983.
74. Chen, X. et al. (2014) The histone deacetylase SIRT6 suppresses the expression of the RNA-binding protein PCBP2 in glioma. Biochem. Biophys. Res. Commun., 446, 364-369.
75. Makeyev, A.V. et al. (2002) The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. RNA, 8, 265-278.
76. Marquardt, J.U. et al. (2013) Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology, 58, 1054-1064.
77. Zhang, Z.G. et al. (2014) Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal-regulated kinase signaling pathway. Mol. Med. Rep., 9, 882-888.
78. Han, Z. et al. (2014) Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int. J. Clin. Exp. Pathol., 7, 4774-4781.
79. Cai, Y. et al. (2014) Radiosensitization effect of overexpression of adenovirus-mediated SIRT6 on A549 non-small cell lung cancer cells. Asian Pac. J. Cancer Prev., 15, 7297-7301.
80. Wushou, A. et al. (2014) Twist-1 up-regulation in carcinoma correlates to poor survival. Int. J. Mol. Sci., 15, 21621-21630.
81. Azuma, Y. et al. (2015) SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. J. Surg. Oncol., 112, 231-237.
82. Kim, E.J. et al. (2015) Cyclic AMP signaling reduces sirtuin 6 expression in non-small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf-MEK-ERK (Raf/mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase) pathway. J. Biol. Chem., 290, 9604-9613.
83. Ming, M. et al. (2014) SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res., 74, 5925-5933.
84. Liu, Y. et al. (2013) Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. Protein Cell, 4, 702-710.
85. Piao, J. et al. (2013) Sirt6 regulates postnatal growth plate differentiation and proliferation via Ihh signaling. Sci. Rep., 3, 3022.
86. Hagerling, C. et al. (2014) Balancing the innate immune system in tumor development. Trends Cell Biol, 25, 214-220.
87. Bauer, I. et al. (2012) The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J. Biol. Chem., 287, 40924-40937.
88. Fernando, R.I. et al. (2011) IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res., 71, 5296-5306.
89. Balkwill, F. (2006) TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev., 25, 409-416.
90. Van Gool, F. et al. (2009) Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med., 15, 206-210.
91. Kawahara, T.L. et al. (2009) SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell, 136, 62-74.
92. Bassères, D.S. et al. (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene, 25, 6817-6830.
93. Das, C. et al. (2009) CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature, 459, 113-117.
94. Lin, Z. et al. (2013) USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep., 5, 1639-1649.
95. Zhang, J. et al. (2014) The histone acetyltransferase hMOF suppresses hepatocellular carcinoma growth. Biochem. Biophys. Res. Commun., 452, 575-580.
96. Feng, X.X. et al. (2015) Sirtuin 6 promotes transforming growth factor-β1/H2O2/HOCl-mediated enhancement of hepatocellular carcinoma cell tumorigenicity by suppressing cellular senescence. Cancer Sci., 106, 559-566.
97. Lefort, K. et al. (2013) A miR-34a-SIRT6 axis in the squamous cell differentiation network. EMBO J., 32, 2248-2263.
98. Wang, D. et al. (2014) The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer. DNA Cell Biol., 33, 581-590.
99. Khongkow, M. et al. (2013) SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis, 34, 1476-1486.
100. Thirumurthi, U. et al. (2014) MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci. Signal., 7, ra71.
101. Orellana, M.E. et al. (2015) Expression of SIRT2 and SIRT6 in retinoblastoma. Ophthalmic Res., 53, 100-108.
102. Sociali, G. et al. (2015) Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. Eur. J. Med. Chem., 102, 530-539.
103. Lu, C.T. et al. (2014) The potential of SIRT6 and SIRT7 as circulating markers for head and neck squamous cell carcinoma. Anticancer Res., 34, 7137-7143.
104. Wang, J.C. et al. (2011) Histone deacetylase in chronic lymphocytic leukemia. Oncology, 81, 325-329.
105. Cagnetta, A. et al. (2015) APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells. Clin. Cancer Res., 21, 3934-3945.
106. Kugel, S. et al. (2015) Identification of and molecular basis for SIRT6 loss-of-function point mutations in cancer. Cell Rep, 13, 479-488.
107. Ronnebaum, S.M. et al. (2013) The ubiquitin ligase CHIP prevents SirT6 degradation through noncanonical ubiquitination. Mol. Cell. Biol., 33, 4461-4472.
108. Stöhr, R. et al. (2015) ITCH modulates SIRT6 and SREBP2 to influence lipid metabolism and atherosclerosis in ApoE null mice. Sci. Rep., 5, 9023.
109. Yuan, J. et al. (2010) USP10 regulates p53 localization and stability by deubiquitinating p53. Cell, 140, 384-396.
110. Rizza, W. et al. (2014) What are the roles of calorie restriction and diet quality in promoting healthy longevity? Ageing Res. Rev., 13, 38-45.
111. Sharma, A. et al. (2013) The role of SIRT6 protein in aging and reprogramming of human induced pluripotent stem cells. J. Biol. Chem., 288, 18439-18447.
112. Lin, H. (2013) Modulators for sirt6 and assays for screening same. Google Patents. US20130345155, CN103403553 A, WO2012088268A2, WO2012088268A3.
113. Sauve, A. et al. (2013) Activation and activators of sirt6. Google Patents. US20130029930 A1, WO2011081945A2, WO2011081945A3.
114. Bruzzone, S. et al. (2013) Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr. Pharm. Des., 19, 614-623.
115. Feldman, J.L. et al. (2013) Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins. J. Biol. Chem., 288, 31350-31356.
116. Kokkonen, P. et al. (2012) Peptides and Pseudopeptides as SIRT6 Deacetylation Inhibitors. ACS Med. Chem. Lett., 3, 969-974.
117. Parenti, M.D. et al. (2014) Discovery of novel and selective SIRT6 inhibitors. J. Med. Chem., 57, 4796-4804.
118. Sinclair, D.A. et al. (2014) Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol., 54, 363-380.